CareMax, Inc. (CMAX)
NASDAQ: CMAX · Real-Time Price · USD
0.720
+0.053 (7.96%)
At close: Nov 22, 2024, 4:00 PM
0.737
+0.017 (2.36%)
After-hours: Nov 22, 2024, 7:55 PM EST
CareMax Stock Forecast
CMAX's stock price has decreased by -96.63% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 1 analyst with a 12-month price forecast for CareMax stock has a target of 6.40, which predicts an increase of 788.89% from the current stock price of 0.72.
Analyst Consensus: Hold
* Price targets were last updated on Apr 1, 2024.
Analyst Ratings
According to 1 stock analyst, the rating for CareMax is "Hold". This means that the analyst believes this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 2 | 2 | 2 | 2 | 2 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| UBS | UBS | Hold Maintains $7 → $6.4 | Hold | Maintains | $7 → $6.4 | +788.89% | Apr 1, 2024 |
| UBS | UBS | Strong Buy → Hold Downgrades $150 → $30 | Strong Buy → Hold | Downgrades | $150 → $30 | +4,066.67% | Nov 17, 2023 |
| Piper Sandler | Piper Sandler | Buy → Hold Downgrades $60 | Buy → Hold | Downgrades | $60 | +8,233.33% | Nov 10, 2023 |
| UBS | UBS | Strong Buy Maintains $300 → $180 | Strong Buy | Maintains | $300 → $180 | +24,900.00% | Jan 6, 2023 |
| Truist Securities | Truist Securities | Hold Initiates $225 | Hold | Initiates | $225 | +31,150.00% | Sep 7, 2022 |
Financial Forecast
Revenue This Year
848.79M
from 751.10M
Increased by 13.01%
Revenue Next Year
1.12B
from 848.79M
Increased by 32.42%
EPS This Year
-29.73
from -183.32
EPS Next Year
-19.60
from -29.73
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 936.5M | 1.3B | 1.5B | ||
| Avg | 848.8M | 1.1B | 1.3B | ||
| Low | 757.0M | 944.3M | 1.1B |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 24.7% | 53.4% | 29.2% | ||
| Avg | 13.0% | 32.4% | 14.0% | ||
| Low | 0.8% | 11.3% | -1.7% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | -21.87 | -16.61 | -5.20 |
| Avg | -29.73 | -19.60 | -8.74 |
| Low | -36.72 | -22.16 | -11.94 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.